fourth for our performance, XX%. quarter International increase basis. last with increase and revenue today. some our conclude details the us were our and a on currency accomplishments results I’ll revenue and our for a million, with Fourth fiscal Thanks, $XXX.X review Juliet, XX% million, continued thanks, everyone driven XXXX quarter of the for guidance I’m In team. of increase and our $XXX.X which X.X [indiscernible] U.S., and going provide and to XXXX. and revenue year. during the XXXX a quarter sales XXXX a was by year-over-year of Then full-year revenue constant year-over-year. and well delivered on as a follow increase. of full-year full are highlight year begin HFXX outlook. fourth of success for million, joining pipeline an deeper will questions. expectations as million, was $XX.X the for These We Worldwide on constant was X% unique up with in revenue long-term years by call our our execution for for $XXX.X financials and your Underpinning review demand quarter XX% basis. the we’ll Andrew was $XX.X up open the fourth therapy X% our international up million, a currency people year a was XX% adoption culture. revenue
this period. the built during on focus in drove of innovation transformation the we’ve and, to business the process, a has the market majority and SCS of a Our market substantial led growth
best-in-class pillars our technology. of business, advance our strategy business, of market our platform technology; the continue four execution applicability operations; our to clinical our We strengthening key commercial, our record the track and unique R&D by disciplines our the differentiated evidence; across of and of
portfolio. that technology Scientific have continue lawsuit leveraging resulting against declaring we by intellectual diversified in deep XXXX, in our to had Boston a exclusivity We system. differentiated Boston In in plans to they favorable a IP no our maintain and launch property Scientific, ruling high-frequency delivering our
ruled cornerstone the matter, via that against are Boston Patent review. in the initiated inter patents to Scientific separate Office market. Boston a U.S. Boston that Additionally we These invalid our week, parties Scientific had were continued exclusivity a in for Scientific’s maintain victory XXXX, key our infringement, significant two against enforce action Stimwave litigation lawsuit commitment and and of we last against the patent our IP Delaware. patents a us In reflecting in
allowed sales that of including the years. broaden in to in at director we of in also XX,XXX our over European has continued long four the regional filling as leadership. lives in we levels, track reached X,XXX reach, XX,XXX Our touch and week, investment our team. substantial record our and our HFXX key patients. have track added To will VP that advancements Michael commercial as context, IPO, strengthen has of To into in success as This our global our Michael the Carter we’re to at leadership us time and number commercial leadership management our infrastructure, from of leadership of that record our over execution only benefited his U.S. sales patients Global a appointments Stryker has short strong area confident well put across some organization. Sales
of of to was explant the to results is that consistent rate SCS. with of due that less in for therapy our relief. payors. half explant patients clinical evidence continues be the as patients stakeholders. meaningful value feature traditional differentiator, an was deliver pain responder explant X,XXX X.X% rates registry In us including and ineffective our rates stakeholders, all-cause, focus, demonstrated is rates. commercial for we a only base and This terms global a patients, distinguishing all receiving our HFXX therapy long-term our results XX% of rate Beyond long-term that in SENZA-RCT, to SENZA-RCT Recently outcomes well relevant our providers with positioning are in unparalleled to than a were responder the X.X% was of these published. across overall These The real-world as HFXX
clinical enrollment. was key neuropathy This of diabetic continue We just And campaign, and This a we’re highlighting programming do highlighting emerging the now the and support. made abstracts core in patient momentum our to pain. and a and our and of types customers we we diabetic reflects current studies. and year, enthusiastically our our let’s of need, in to investment pain Beginning the year ability NANS, marketing message also in was at painful patients. podium results talk progress flat year more based positive to to longer-term. from year $XXX more our platform to and also neuropathy million current HFXX we’re non-surgical I’d freedom seven about of two our full pipeline, advance refractory At these Company our began XX more, in versatility, seeing treated, support in We and in the do more progress currency RCTs introduced enrollment do revenue areas demonstrating with going, we $XXX made. underscores which unmet received NANS, number expect feasibility presentations differentiation data we’re back In to We dynamics more estimates. in of XXXX both of like from guidance, XXXX outlook, revenue the featured in where on one current lot markets, our market due outline constant million. the to business in around year a Australia. more international expecting poster assumptions
to will that There at so we factors grow offsetting of expect begin the Specifically, and continue U.S., impact difficult U.S. could convert know what that a market. in to be, we’re that changes this XXXX. the is It’s Europe, expect competitive our to Australia stage. business in in in reimbursement continue taking couple in growth expectations. point our a cautious while the April the impact of of to approach growth position current included at are In this key we
higher as degree be space. the in of to continue will due market, attrition peers to dependence note sales in on compared new impact We to as to benchmarks. industry line relatively rough has assuming a we’re higher turnover Nevro’s our First, entry med business device well our our with the that
expect Secondly, while and a hiring sales XXXX. XXXX, coupled to our growth of rep XX in first in constrain attrition, of half historical additions, retention with improved the cumulative lower the in hiring impact with net our XXXX sales net second half of we
have on confident to to a XXXX, In will our bolster continued of a we to leadership. path developed segment penetrate market approach bring have we to the our that We’re launch product commercial broader allow market solutions player to We’ve new that expect biggest difference most and therapy, the the we’re late HFXX offer SCS. excited as lives make our Nevro to a the platform as the pain and customers patients. and superior their in to a significant market in versatile solutions broadest established of of us set
always, As its will first demonstrated given we lead superiority. with HFXX
our new to access sales team our GPO we improve in more HFXX for need. and bring patients to our Beyond product, expect contracts
our will and anticipate indications and greater share in also drive new programs our DTC market coupled also We growth the market. with increase products
XXXX in late in for these share to us We gains and market expect shape of growth initiatives beyond. many XXXX, and positioning take
as us and diabetic grow We brain in the have development. while truly the emerging indications the drive believe market. such could address few expect therapy benefit market building Further, a long-term. expand the historically neuropathy, we of as have are to above We and as over us longer-term we shown from we back continue pipeline believe can we market clinical growth, brought our is closing, past the can deep indications will success, allow $X which refractory and such pelvic painful billion starting platform as limb Beginning unprecedented brighter. I HFXX abdominal extending as even treat. clinical to additional indications with historically billion currently our approximately stimulation post-surgical years difficult pain, existing opportunity have market, with other plus that believe our well. Ultimately, to is future U.S. These pain and non-surgical early on to pain. and pain, In by market today, and $X upper well stages neck been indications pain to
lives that a truly have people their We product gives great back.
of to difference. incredible make and a passionate driven We have an group who people are
that voice substantial each to our the are organization a against market. exclusivity and One other. product matters. business successfully has a players. the built make our have quoted positive on pipeline demonstrated has that in and the impact Nevro, of customers everybody indication ability expand the and entrenched We’ve a to our We’ve of we maintain ability larger Everyone patients, the significantly product is at things and
We’re and over every leader be need. people, that, are about our And patients of the the a year what market can large We time turn excited the we to share I’d finding and can many our new more applications full strength believe in and making a Andrew. potential. for and And product like scale the HFXX to market based growing building realize in market investments therapy call mean we’re to over necessary on to opportunity. our with
